Stockscreener 앱 받기
0.4607
1.92%
0.0087
시간 외 거래:
.42
-0.0407
-8.83%
전일 마감가:
$0.452
열려 있는:
$0.45
하루 거래량:
241.56K
Relative Volume:
0.30
시가총액:
$9.92M
수익:
$275.60K
순이익/손실:
$-8.33M
주가수익비율:
-0.9974
EPS:
-0.4619
순현금흐름:
$-5.40M
1주 성능:
+27.62%
1개월 성능:
+0.37%
6개월 성능:
-35.33%
1년 성능:
-53.74%
1일 변동 폭
$0.4106
$0.476
1주일 범위
$0.3462
$0.49
52주 변동 폭
$0.305
$2.00
Nexalin Technology Inc Stock (NXL) Company Profile
명칭
Nexalin Technology Inc
전화
(832) 260-0222
주소
1776 YORKTOWN, HOUSTON
Compare NXL vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
0.4607 | 9.92M | 275.60K | -8.33M | -5.40M | -0.4619 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Nexalin Technology Inc 주식(NXL)의 최신 뉴스
Nexalin Technology (NXL) plans new 7M-share incentive pool and reverse split authority - Stock Titan
Price to earnings forward of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
NXL Q1 2026 Earnings: EPS Misses Estimates, Stock Declines 5%Margin Compression Risk - dars.gov.et
NXL Should I Buy - Intellectia AI
Form PRE 14A Nexalin Technology Inc For: 29 June By Investing.com - Investing.com South Africa
Nexalin Technology (NXL) seeks shareholder votes for equity plan, reverse split - Stock Titan
NexaLine Technology Registers 1.2 Million Shares for Resale - Moomoo
Nexalin Technology | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Nexalin Technology Secures US Patent for Deep-Brain Stimulation Targeting Insomnia - Sleep Review
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Stage, Stock Rises 4%Profit Guidance Range - dars.gov.et
Nexalin Technology, Inc. Actuals & Estimates (NASDAQ:NXL) - TradingView
$Nexalin Technology (NXL.US)$ - Moomoo
Nexalin Technology Inc (NXLIW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NXL Forecast — Price Target — Prediction for 2027 - TradingView
Nexalin Technology Inc (NXL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NXL Stock Price, Quote & Chart - ChartMill
Nexalin Technology Announces that the Investigator of Its - GlobeNewswire
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform - Yahoo Finance
Nexalin Technology Inc (NXL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exclusive: Nexalin Brazil trial shows benefits across anxiety, sleep and quality of life - MSN
Nexalin Technology, Inc. Financial Disclosures & SEC Filings - TradingView
Nexalin Technology Inc (NXL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nexalin Technology Inc (NXL) Institutional Confidence - TradingKey
Nexalin Technology Inc (NXL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc (NXL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nexalin Technology Inc (NXL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nexalin Technology Inc (NXLIW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc (NXLIW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nexalin Technology Inc (NXLIW) Institutional Confidence - TradingKey
Nexalin Technology Inc (NXLIW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nexalin Technology Adopts Second Amended and Restated Bylaws Effective June 16, 2026 - Minichart
Nexalin Technology Inc (NXLIW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nexalin Overhauls Bylaws, Modernizes Corporate Governance Framework - TipRanks
Nexalin Technology (NXL) overhauls bylaws, lowers quorum and adds exclusive forum rules - Stock Titan
Nexalin Technology Inc (NXL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nexalin abstracts accepted at NYC neuromodulation conference By Investing.com - Investing.com South Africa
Nexalin Technology Inc (NXLIW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nexalin Technology Inc (NXLIW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nexalin Technology Inc (NXLIW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nexalin Technology Announces Acceptance of Two Clinical Abstracts for Presentation At 2026 Nyc Neuromodulation Conference - marketscreener.com
Nexalin abstracts accepted at NYC neuromodulation conference - Investing.com
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life - Yahoo Finance
Nexalin Technology, Inc. Announces Acceptance of Clinical Abstracts Showcasing DIFS™ Treatment Efficacy at 2026 NYC Neuromodulation Conference - Quiver Quantitative
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Amid Continued Development PhaseRevenue Beat Analysis - dars.gov.et
Nexalin reports positive results from anxiety disorder trial By Investing.com - Investing.com Nigeria
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life - Sahm
Nexalin Technology, Inc. (NXL) stock price, news, quote and history - Yahoo Finance Australia
Nexalin Technology Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains 2%ROA Comparison - newsline.com
NXL Q1 2026 Earnings: EPS Misses Estimates, Stock Gains Despite Wider LossEarnings Surprise Score - newsline.com
Nexalin reports positive clinical trial results for anxiety and insomnia - grafa.com
Nexalin reports positive results from anxiety disorder trial - Investing.com UK
Nexalin Technology Inc (NXL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.36%
자본화:
|
볼륨(24시간):